Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?

Clark, Amy S; Makhlin, Igor; DeMichele, Angela

Clark, Amy S; Makhlin, Igor; DeMichele, Angela.

Afiliación

Clark AS; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. amy.clark@uphs.upenn.edu.
Makhlin I; Abramson Cancer Center, Philadelphia, Pennsylvania.
DeMichele A; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Clin Cancer Res ; 27(2): 371-373, 2021 01 15.

Article en En | MEDLINE | ID: mdl-33144339

RESUMEN

PI3K and CDK4/6 inhibitors (CDK4/6i) are targeted therapies approved to treat advanced breast cancer; CDK4/6is are more widely used. Here, we discuss trials that examine PI3K inhibitors with novel drug combinations, including a CDK4/6i, given data implicating the pathway in CDK 4/6 resistance.See related articles by Lu et al., p. 408, and Tolaney et al., p. 418.

Asunto(s)

Neoplasias de la Mama; Fosfatidilinositol 3-Quinasas; Aminopiridinas; Neoplasias de la Mama/tratamiento farmacológico; Neoplasias de la Mama/genética; Quinasa 4 Dependiente de la Ciclina/genética; Quinasa 6 Dependiente de la Ciclina/genética; Femenino; Goserelina; Humanos; Morfolinas; Tamoxifeno; Tiazoles

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Fosfatidilinositol 3-Quinasas Límite: Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google